Jazz Pharmaceuticals (JAZZ) EBIT: 2009-2025
Historic EBIT for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $57.5 million.
- Jazz Pharmaceuticals' EBIT fell 77.90% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.6 million, marking a year-over-year decrease of 30.19%. This contributed to the annual value of $716.6 million for FY2024, which is 23.86% up from last year.
- As of Q3 2025, Jazz Pharmaceuticals' EBIT stood at $57.5 million, which was up 202.89% from -$55.9 million recorded in Q2 2025.
- Over the past 5 years, Jazz Pharmaceuticals' EBIT peaked at $260.2 million during Q3 2024, and registered a low of -$263.4 million during Q4 2022.
- Over the past 3 years, Jazz Pharmaceuticals' median EBIT value was $141.8 million (recorded in 2023), while the average stood at $129.7 million.
- Per our database at Business Quant, Jazz Pharmaceuticals' EBIT crashed by 633.39% in 2022 and then soared by 596.17% in 2023.
- Jazz Pharmaceuticals' EBIT (Quarterly) stood at $49.4 million in 2021, then tumbled by 633.39% to -$263.4 million in 2022, then spiked by 146.51% to $122.5 million in 2023, then soared by 55.73% to $190.8 million in 2024, then crashed by 77.90% to $57.5 million in 2025.
- Its EBIT was $57.5 million in Q3 2025, compared to -$55.9 million in Q2 2025 and $190.8 million in Q4 2024.